Limits...
Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection.

Zhang Q, Xu M, Qu Y, Li Z, Zhang Q, Cai X, Lu L - Mol Med Rep (2015)

Bottom Line: Finally, the target genes of the miRNAs were predicted and classified using gene ontology analysis.A total of 140 miRNAs were detected in the S1‑S4 patient groups, and their expression levels were >2‑fold higher compared with those in the S0 group.The numbers of miRNAs differentially expressed in the S1‑S4 patient groups were 48, 97, 84 and 56, respectively, with 12 miRNAs differentially expressed at all stages, 10 of which were upregulated and two of which were downregulated.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiao‑Tong University School of Medicine, Shanghai 200080, P.R. China.

ABSTRACT
Considering the limitations of liver biopsy, reliable non‑invasive serum biomarkers of liver fibrosis are required for early diagnosis. The present study analyzed the expression profile of circulating micro (mi)RNAs during the development and progression of hepatic fibrosis in patients with chronic hepatitis B virus (HBV) infection, aiming to identify novel earlier diagnostic biomarkers. Fresh plasma samples were collected from 50 patients diagnosed with chronic HBV infection and hepatic fibrosis. These patients were classified into five groups (S0, S1, S2, S3 and S4; n=10 per group) based on Scheuer's staging criteria. The differential expression of the circulating miRNAs was determined by performing miRNA microarray hybridization. Finally, the target genes of the miRNAs were predicted and classified using gene ontology analysis. A total of 140 miRNAs were detected in the S1‑S4 patient groups, and their expression levels were >2‑fold higher compared with those in the S0 group. The numbers of miRNAs differentially expressed in the S1‑S4 patient groups were 48, 97, 84 and 56, respectively, with 12 miRNAs differentially expressed at all stages, 10 of which were upregulated and two of which were downregulated. The target genes of the miRNAs identified were found to be involved in 100 signal transduction pathways, the majority of which affected hepatic fibrosis via the TGF‑/Smad, Wnt, MAPK, Jak/STAT and VEGF pathways. The differential expression levels of miRNAs were closely associated with the staging of hepatic fibrosis. The results of the present study provide evidence to facilitate the development and application of non‑invasive biomarkers for earlier diagnosis of hepatic fibrosis.

Show MeSH

Related in: MedlinePlus

Trend analysis of different miRNAs. The expression trends of different miRNAs associated with the progression of hepatic fibrosis is shown. The expression levels of hsa-miR-2861, hsa-miR-345-3p, hsa-miR-3620-3p, hsa-miR-3656, hsa-miR-371a-5p, hsa-miR-4646-5p, hsa-miR-4651, hsa-miR-4695-5p, hsa-miR-4800-5p and hsa-miR-638 were upregulated and the expression levels of hsa-miR-486-3p and hsa-miR-497-5p were downregulated. miR/miRNA, microRNA.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581744&req=5

f3-mmr-12-04-5647: Trend analysis of different miRNAs. The expression trends of different miRNAs associated with the progression of hepatic fibrosis is shown. The expression levels of hsa-miR-2861, hsa-miR-345-3p, hsa-miR-3620-3p, hsa-miR-3656, hsa-miR-371a-5p, hsa-miR-4646-5p, hsa-miR-4651, hsa-miR-4695-5p, hsa-miR-4800-5p and hsa-miR-638 were upregulated and the expression levels of hsa-miR-486-3p and hsa-miR-497-5p were downregulated. miR/miRNA, microRNA.

Mentions: Log standardization was applied to the different miRNAs to eliminate the effect from varied baseline values and to facilitate trend display in the different groups (Fig. 3). This demonstrated that hsa-miR-4695-5p, hsa-miR-486-3p and hsa-miR-497-5p were suitable for use as markers to differentiate between the different stages of hepatic fibrosis due to HBV infection.


Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection.

Zhang Q, Xu M, Qu Y, Li Z, Zhang Q, Cai X, Lu L - Mol Med Rep (2015)

Trend analysis of different miRNAs. The expression trends of different miRNAs associated with the progression of hepatic fibrosis is shown. The expression levels of hsa-miR-2861, hsa-miR-345-3p, hsa-miR-3620-3p, hsa-miR-3656, hsa-miR-371a-5p, hsa-miR-4646-5p, hsa-miR-4651, hsa-miR-4695-5p, hsa-miR-4800-5p and hsa-miR-638 were upregulated and the expression levels of hsa-miR-486-3p and hsa-miR-497-5p were downregulated. miR/miRNA, microRNA.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581744&req=5

f3-mmr-12-04-5647: Trend analysis of different miRNAs. The expression trends of different miRNAs associated with the progression of hepatic fibrosis is shown. The expression levels of hsa-miR-2861, hsa-miR-345-3p, hsa-miR-3620-3p, hsa-miR-3656, hsa-miR-371a-5p, hsa-miR-4646-5p, hsa-miR-4651, hsa-miR-4695-5p, hsa-miR-4800-5p and hsa-miR-638 were upregulated and the expression levels of hsa-miR-486-3p and hsa-miR-497-5p were downregulated. miR/miRNA, microRNA.
Mentions: Log standardization was applied to the different miRNAs to eliminate the effect from varied baseline values and to facilitate trend display in the different groups (Fig. 3). This demonstrated that hsa-miR-4695-5p, hsa-miR-486-3p and hsa-miR-497-5p were suitable for use as markers to differentiate between the different stages of hepatic fibrosis due to HBV infection.

Bottom Line: Finally, the target genes of the miRNAs were predicted and classified using gene ontology analysis.A total of 140 miRNAs were detected in the S1‑S4 patient groups, and their expression levels were >2‑fold higher compared with those in the S0 group.The numbers of miRNAs differentially expressed in the S1‑S4 patient groups were 48, 97, 84 and 56, respectively, with 12 miRNAs differentially expressed at all stages, 10 of which were upregulated and two of which were downregulated.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiao‑Tong University School of Medicine, Shanghai 200080, P.R. China.

ABSTRACT
Considering the limitations of liver biopsy, reliable non‑invasive serum biomarkers of liver fibrosis are required for early diagnosis. The present study analyzed the expression profile of circulating micro (mi)RNAs during the development and progression of hepatic fibrosis in patients with chronic hepatitis B virus (HBV) infection, aiming to identify novel earlier diagnostic biomarkers. Fresh plasma samples were collected from 50 patients diagnosed with chronic HBV infection and hepatic fibrosis. These patients were classified into five groups (S0, S1, S2, S3 and S4; n=10 per group) based on Scheuer's staging criteria. The differential expression of the circulating miRNAs was determined by performing miRNA microarray hybridization. Finally, the target genes of the miRNAs were predicted and classified using gene ontology analysis. A total of 140 miRNAs were detected in the S1‑S4 patient groups, and their expression levels were >2‑fold higher compared with those in the S0 group. The numbers of miRNAs differentially expressed in the S1‑S4 patient groups were 48, 97, 84 and 56, respectively, with 12 miRNAs differentially expressed at all stages, 10 of which were upregulated and two of which were downregulated. The target genes of the miRNAs identified were found to be involved in 100 signal transduction pathways, the majority of which affected hepatic fibrosis via the TGF‑/Smad, Wnt, MAPK, Jak/STAT and VEGF pathways. The differential expression levels of miRNAs were closely associated with the staging of hepatic fibrosis. The results of the present study provide evidence to facilitate the development and application of non‑invasive biomarkers for earlier diagnosis of hepatic fibrosis.

Show MeSH
Related in: MedlinePlus